Beyond Flatiron: The Rising Power Of Oncology Clinical Data CompaniesIt will behoove drug makers to anticipate real world efficacy prior to launch, as the limiting factor for commercialization could soon be not whether a drug is approved by the FDA, based on clinical trial data, but whether it’s validated by clinical data companies, based on real-world performance.

[Collection]It will behoove drug makers to anticipate real world efficacy prior to launch, as the limiting factor for commercialization could soon be not whether a drug is approved by the FDA, based on clinical trial data, but whether it’s validated by clinical data companies, based on real-world performance.https://www.forbes.com/sites/davidshaywitz/2018/03/09/beyond-flatiron-the-rising-power-of-oncology-clinical-data-companies/